His performance status was initially good; however, because of chronic kidney disease with clinically significant proteinuria, anti‐VEGF treatment (e.g., bevacizumab) and TKIs such as lenvatinib were considered unsuitable. This evidence concerns the gene VEGFA and chronic kidney disease.